The following tables contain unaudited consolidated quarterly financial information for 2019 and 2018 that has been updated to reflect the restatement and revision of the Company’s consolidated financial statements as described in Note 2—Restatement of Consolidated Financial Statements. The restatement and revision had no impact on net cash flows from operating, investing or financing activities. The Company has not amended its previously filed Annual Report on Form 10-K for the year ended December 31, 2018 or its Quarterly Reports on Form 10-Q for the Affected Periods. The financial information that has been previously filed or otherwise reported for the Affected Periods is superseded by the information in this Annual Report, and the financial statements and related financial information for the Affected Periods contained in such previously filed reports should no longer be relied upon.

Condensed Consolidated Statements of Operations



	Three Months Ended			Three Months Ended			Six Months Ended			Three Months Ended			Nine Months Ended			Three Months Ended
	March 31, 2019			June 30, 2019			June 30, 2019			September 30, 2019			September 30, 2019			December 31, 2019
	(Restated)			(Restated)			(Restated)			(Restated)			(Restated)
License and collaboration revenue	$	1,100		$	1,101		$	2,201		$	1,100		$	3,301		$	1,176
Government research contracts and grants revenue	—			—			—			216			216			203
Total revenue	1,100			1,101			2,201			1,316			3,517			1,379
Operating expenses:
Research and development	4,827			6,189			11,016			8,598			19,614			5,558
General and administrative	2,994			3,311			6,305			2,290			8,595			1,817
Total operating expenses	7,821			9,500			17,321			10,888			28,209			7,375
Operating loss	(6,721		)	(8,399		)	(15,120		)	(9,572		)	(24,692		)	(5,996		)
Other income (expense), net:
Interest income	28			68			96			53			149			28
Interest expense	—			(1		)	(1		)	—			(1		)	(1		)
Other income, net	56			36			92			23			115			21
Total other income (expense), net	84			103			187			76			263			48
Net loss and comprehensive loss	$	(6,637	)	$	(8,296	)	$	(14,933	)	$	(9,496	)	$	(24,429	)	$	(5,948	)
Net loss per share, basic and diluted	$	(0.25	)	$	(0.32	)	$	(0.57	)	$	(0.36	)	$	(0.94	)	$	(0.22	)
Weighted-average common shares outstanding, basic and diluted	26,066,064			26,069,734			26,067,909			26,189,454			26,108,870			26,685,133



	Three Months Ended			Three Months Ended			Six Months Ended			Three Months Ended			Nine Months Ended			Three Months Ended
	March 31, 2018			June 30, 2018			June 30, 2018			September 30, 2018			September 30, 2018			December 31, 2018
	(Restated)			(Restated)			(Restated)			(Restated)			(Restated)
License and collaboration revenue	$	649		$	649		$	1,298		$	648		$	1,946		$	4,036
Research and development services revenue	9			—			9			—			9			—
Total revenue	658			649			1,307			648			1,955			4,036
Operating expenses:
Research and development	6,335			6,176			12,511			5,697			18,208			4,837
General and administrative	2,880			2,620			5,500			3,295			8,795			2,712
Total operating expenses	9,215			8,796			18,011			8,992			27,003			7,549
Operating loss	(8,557		)	(8,147		)	(16,704		)	(8,344		)	(25,048		)	(3,513		)
Other income (expense), net:
Interest income	44			115			159			83			242			55
Interest expense	(262		)	(261		)	(523		)	(262		)	(785		)	(262		)
Other income, net	—			4			4			28			32			40
Total other income (expense), net	(218		)	(142		)	(360		)	(151		)	(511		)	(167		)
Net loss and comprehensive loss	$	(8,775	)	$	(8,289	)	$	(17,064	)	$	(8,495	)	$	(25,559	)	$	(3,680	)
Net loss per share, basic and diluted	$	(0.35	)	$	(0.32	)	$	(0.67	)	$	(0.33	)	$	(0.99	)	$	(0.14	)
Weighted-average common shares outstanding, basic and diluted	25,026,890			26,039,169			25,535,827			26,046,666			25,707,978			26,056,504

Condensed Consolidated Balance Sheets



	March 31, 2019			June 30, 2019			September 30, 2019			December 31, 2019
	(Restated)			(Restated)			(Restated)
ASSETS
Current assets:
Cash and cash equivalents	$	6,077		$	22,438		$	15,549		$	13,711
Restricted cash	—			8,286			5,651			—
Contracts and grants receivable	—			—			216			419
Deferred offering costs	49			49			49			49
Prepaid expenses and other current assets	1,062			1,237			982			1,545
Total current assets	7,188			32,010			22,447			15,724
Restricted cash	539			2,060			1,345			540
Intangible assets	75			75			75			75
Other assets	501			473			444			419
Property and equipment, net	11,657			11,054			10,569			10,506
Right-of-use lease assets	1,833			1,837			1,837			1,833
Total assets	$	21,793		$	47,509		$	36,717		$	29,097
LIABILITIES AND STOCKHOLDERS’ (DEFICIT) EQUITY
Current liabilities:
Accounts payable	$	1,510		$	957		$	2,495		$	1,602
Accrued compensation	2,082			1,412			1,507			437
Accrued outside research and development services	817			789			1,382			1,013
Accrued legal and professional fees	258			295			168			616
Other accrued expenses	516			633			878			553
Deferred revenue, current portion	4,401			4,401			4,401			4,428
Research and development service obligation liability, current portion	—			8,286			5,651			3,088
Lease liabilities, current portion	1,139			1,151			1,156			1,162
Total current liabilities	10,723			17,924			17,638			12,899
Deferred revenue, net of current portion	5,926			4,825			3,725			7,076
Lease liabilities, net of current portion	5,544			5,395			5,249			5,100
Research and development service obligation liability, net of current portion	—			1,521			806			727
Research and development funding arrangement liability, related party	—			25,000			25,000			25,000
Other long-term liabilities	335			1,630			1,634			578
Total liabilities	22,528			56,295			54,052			51,380
Commitments and contingencies
Stockholders’ equity (deficit)
Common stock $0.0001 par value	3			3			3			3
Additional paid-in-capital	195,661			195,906			196,853			197,853
Treasury stock at cost	(155		)	(155		)	(155		)	(155		)
Accumulated deficit	(196,244		)	(204,540		)	(214,036		)	(219,984		)
Total stockholders' (deficit) equity	(735		)	(8,786		)	(17,335		)	(22,283		)
Total liabilities and stockholders’ (deficit) equity	$	21,793		$	47,509		$	36,717		$	29,097



	March 31, 2018			June 30, 2018			September 30, 2018			December 31, 2018
	(Restated)			(Restated)			(Restated)			(Restated)
ASSETS
Current assets:
Cash and cash equivalents	$	28,100		$	20,984		$	12,173		$	8,194
Deferred offering costs	49			49			49			49
Prepaid expenses and other current assets	889			576			584			1,107
Total current assets	29,038			21,609			12,806			9,350
Restricted cash	539			539			539			539
Intangible assets	75			75			75			75
Other assets	176			161			146			530
Property and equipment, net	16,474			16,327			16,129			15,868
Total assets	$	46,302		$	38,711		$	29,695		$	26,362
LIABILITIES AND STOCKHOLDERS’ (DEFICIT) EQUITY
Current liabilities:
Accounts payable	$	828		$	1,056		$	386		$	1,250
Accrued compensation	977			1,380			1,689			1,467
Accrued outside research and development services	1,258			1,408			1,571			563
Accrued legal and professional fees	458			267			305			498
Other accrued expenses	1,194			1,443			1,247			871
Deferred revenue, current portion	2,638			2,595			2,595			4,401
Capital lease obligation, net of current portion	11			11			11			11
Total current liabilities	7,364			8,160			7,804			9,061
Deferred revenue, net of current portion	5,294			4,648			4,000			2,566
Capital lease obligation, net of current portion	19			16			13			10
Other long-term liabilities	—			—			103			289
Facility financing obligation	7,998			7,998			7,998			7,998
Total liabilities	20,675			20,822			19,918			19,924
Commitments and contingencies
Stockholders’ equity (deficit)
Common stock $0.0001 par value	3			3			3			3
Additional paid-in-capital	194,208			194,759			195,142			195,483
Treasury stock at cost	(155		)	(155		)	(155		)	(155		)
Accumulated deficit	(168,429		)	(176,718		)	(185,213		)	(188,893		)
Total stockholders' (deficit) equity	25,627			17,889			9,777			6,438
Total liabilities and stockholders’ (deficit) equity	$	46,302		$	38,711		$	29,695		$	26,362